Alpha-1-antitrypsin mutants, compositions comprising same, and use thereof
AssigneesB. G. Negev Technologies and Applications Ltd., At Ben-Gurion University, The National Institute for Biotechnology In the Negev Ltd.
InventorsYotam LIOR, Eli Chaim LEWIS
Life of this patent
Estimating the term…
Abstract
The present invention includes mutants of human alpha-1-antitrypsin (mhAAT). Further provided are compositions including the mhAAT and use of same, such as for modulating an immune cell, and treating a condition, such as inflammation.
Claims24
A polypeptide comprising the amino acid sequence of EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAF AMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLHTLNQPDSQLQLTTGNGLFLSE GLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDT VFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSS WVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTY DLKSILGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIP MSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK (SEQ ID NO:
- 9), wherein said polypeptide comprises at least one amino acid substitution at a position selected from the group consisting of:
- T22, T68, D74, D202, K243, and K368.
-9. (canceled)
-20. (canceled)
-25. (canceled)
(canceled)
Dependencies are inferred from the claim text.